$397 Million is the total value of Samsara BioCapital, LLC's 57 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ALLK | Exit | ALLAKOS INCcall | $0 | – | -168,200 | -100.0% | -0.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
ALLAKOS INC | 20 | Q3 2023 | 23.0% |
SUTRO BIOPHARMA INC | 20 | Q3 2023 | 10.1% |
SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
ATRECA INC | 16 | Q1 2023 | 7.4% |
IVERIC BIO INC | 15 | Q2 2023 | 5.5% |
ACLARIS THERAPEUTICS INC | 15 | Q3 2023 | 4.8% |
RHYTHM PHARMACEUTICALS INC | 15 | Q3 2023 | 2.4% |
ODONATE THERAPEUTICS INC | 14 | Q1 2022 | 14.9% |
SPRINGWORKS THERAPEUTICS INC | 14 | Q4 2022 | 12.1% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR/A | 2023-08-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR/A | 2023-02-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.